Cresilon's plant-based hemostatic gel TRAUMAGEL receives FDA clearance for life-threatening bleeding control.

Brooklyn-based Cresilon Inc., a biotech company specializing in hemostatic medical devices, has received FDA clearance for its plant-based hemostatic gel, TRAUMAGEL, designed to control life-threatening bleeding in seconds. TRAUMAGEL targets the needs of the U.S. military, government health agencies, EMS systems, and medical professionals who encounter traumatic wounds. This marks Cresilon's second FDA clearance for human use.

August 15, 2024
12 Articles